Therapixel
AI-powered software designed to assist radiologists in breast cancer screening.
What they do
The company manufactures FDA-cleared and CE-marked AI software that analyzes mammograms to flag potential malignant microcalcifications and masses. Hospital breast imaging clinics and breast screening centers use the software to improve cancer detection rates and speed up workflows.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Mammography AI imaging
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- Nice, France
- Region
- Europe
- Founded
- 2013
- Total funding
- $23M raised
Notable investors: Credit Mutuel Innovation, Omnes Capital, Ventech, Regimbeau.